Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
Article Abstract:
The efficacy and safety of 48 weeks of therapy with entecavir with 48 weeks of therapy with lamivudine in the patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B who had not previously received a nucleoside analogue are compared. The results show that the rates of histologic improvement, virologic response and normalization of alanine aminotransferase levels are higher with entecavir than with lamivudine, whereas the safety profiles of the two agents are similar and there is no evidence of viral resistance to entecavir.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Article Abstract:
The efficacy and safety of 48 weeks of therapy with entecavir with 48 weeks of therapy with lamivudine in the patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue are compared. The results show that the rates of histologic, virologic and biochemical improvement are higher with entecavir than with lamivudine, whereas the safety profiles are similar and there is no evidence of viral resistance to entecavir.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
Article Abstract:
The effect of continued therapy as compared to the treatment with adefovir dipivoxil resulting in histologic, virologic, and biochemical improvements in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is evaluated. It is concluded that patients with HBeAg-negative chronic hepatitis B, achieved benefits of adefovir dipivoxil in 48 weeks and in patients treated for 144 weeks, benefits were maintained, with infrequent emergence of viral resistance.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Long-term vasodilator therapy in patients with severe aortic regurgitation. Long-term follow-up of idiopathic chronic pericardial effusion
- Abstracts: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The medical management of depression
- Abstracts: Hospital volume and the outcomes of mechanical ventilation. Hydrocortisone therapy for patients with septic shock
- Abstracts: Death not necessarily end for heart devices. A change of heart guidelines for women. Obesity's role in heart disease requires apples and pears comparison
- Abstracts: Live attenuated versus inactivated influenza vaccine in infants and young children. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis